NASDAQ:GTBP GT Biopharma (GTBP) Stock Price, News & Analysis $2.89 +0.22 (+8.24%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.88 -0.02 (-0.52%) As of 05/23/2025 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About GT Biopharma Stock (NASDAQ:GTBP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GT Biopharma alerts:Sign Up Key Stats Today's Range$2.66▼$2.8950-Day Range$2.15▼$2.8952-Week Range$1.72▼$4.10Volume100,317 shsAverage Volume246,103 shsMarket Capitalization$7.47 millionP/E RatioN/ADividend YieldN/APrice Target$11.00Consensus RatingStrong Buy Company OverviewGT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.Read More… GT Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreGTBP MarketRank™: GT Biopharma scored higher than 63% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingGT Biopharma has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageGT Biopharma has received no research coverage in the past 90 days.Read more about GT Biopharma's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for GT Biopharma are expected to grow in the coming year, from ($6.79) to ($2.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GT Biopharma is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GT Biopharma is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGT Biopharma has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about GT Biopharma's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.74% of the float of GT Biopharma has been sold short.Short Interest Ratio / Days to CoverGT Biopharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GT Biopharma has recently decreased by 23.52%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGT Biopharma does not currently pay a dividend.Dividend GrowthGT Biopharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.74% of the float of GT Biopharma has been sold short.Short Interest Ratio / Days to CoverGT Biopharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GT Biopharma has recently decreased by 23.52%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News Sentiment0.39 News SentimentGT Biopharma has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for GT Biopharma this week, compared to 0 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, GT Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders10.90% of the stock of GT Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 8.15% of the stock of GT Biopharma is held by institutions.Read more about GT Biopharma's insider trading history. Receive GTBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GT Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address GTBP Stock News HeadlinesStocks in play: GT Biopharma, Inc.May 19, 2025 | ca.finance.yahoo.comThis Natural Killer Treatment Could Help Transform How Cancer is TreatedMay 19, 2025 | baystreet.caLittle-known 2021 NYSE “loophole” for Bitcoin enthusiastsWe’re on the edge of what could be a massive parabolic move in Bitcoin that pushes the price past all-time highs… and over $100K. There was a little-known move by the NYSE in late 2021 that opened up a “loophole” for anyone with a regular brokerage account to take advantage of Bitcoin. Combined with a Trump presidency—who says he wants to be known as the first “Crypto President”—this creates an unprecedented opportunity. May 25, 2025 | ProsperityPub (Ad)GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation SignalsMay 19, 2025 | globenewswire.comGT Biopharma Inc.May 18, 2025 | marketwatch.comGT Biopharma appoints new board memberMay 17, 2025 | investing.comGT Biopharma adds Hilary Kramer to Board of DirectorsMay 15, 2025 | investing.comGT Biopharma announces private placement dealMay 14, 2025 | investing.comSee More Headlines GTBP Stock Analysis - Frequently Asked Questions How have GTBP shares performed this year? GT Biopharma's stock was trading at $3.05 on January 1st, 2025. Since then, GTBP stock has decreased by 5.2% and is now trading at $2.89. View the best growth stocks for 2025 here. How were GT Biopharma's earnings last quarter? GT Biopharma, Inc. (NASDAQ:GTBP) released its quarterly earnings data on Thursday, May, 15th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by $0.12. When did GT Biopharma's stock split? GT Biopharma shares reverse split on Monday, February 5th 2024. The 1-30 reverse split was announced on Monday, February 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are GT Biopharma's major shareholders? Top institutional investors of GT Biopharma include DekaBank Deutsche Girozentrale. Insiders that own company stock include Michael Martin Breen and Manu Ohri. View institutional ownership trends. How do I buy shares of GT Biopharma? Shares of GTBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GT Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that GT Biopharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), Meta Platforms (META), CrowdStrike (CRWD) and Intel (INTC). Company Calendar Last Earnings5/15/2025Today5/25/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GTBP Previous SymbolOTCMKTS:OXISD CIK109657 Webwww.gtbiopharma.com Phone(415) 919-4040FaxN/AEmployees8Year Founded1965Price Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+280.6%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($5.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,600,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-257.47% Return on Assets-131.09% Debt Debt-to-Equity RatioN/A Current Ratio1.45 Quick Ratio1.45 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.42 per share Price / Book0.53Miscellaneous Outstanding Shares2,586,000Free Float1,990,000Market Cap$7.47 million OptionableNo Data Beta1.48 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:GTBP) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GT Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GT Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.